Prerna Mewawalla, Myeloma and Transplant Physician, Associate Professor at Drexel University College of Medicine, shared a post on LinkedIn:
“Pleased to join Dr. Binod Dhakal and Dr. Carol Ann Huff for this ongoing Cancer Network training academy series of episodes exploring practical decision-making in relapsed/refractory multiple myeloma.
As anti-CD38 monoclonal antibodies move increasingly into frontline myeloma therapy, one distinction is becoming clinically critical: anti-CD38 exposed is not always the same as anti-CD38 refractory.
In this episode, we discuss how recent treatment history, timing of progression, and disease behavior should shape decision-making in relapsed/refractory multiple myeloma.”
Other articles featuring Prerna Mewawalla on OncoDaily.